

FORM PTO-1449, (modified) To: U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No. 056291-5184	Client Ref. 10/511744 100697-1P US
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant: Joseph Anderson RYAN	
		Appln. No.: To Be Assigned	
		Filing Date: Concurrently	
Date: October 18, 2004		Page 1 of 1	Examiner: Unassigned Group Art Unit: Unassigned

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
	AR					
	BR					
	CR					
	DR					
	ER					
	FR					

FOREIGN PATENT DOCUMENTS

		Document Number	Date MM/YYYY	Country	Inventor/Applicant Name	English Abstract		Translation Readily Available	
						Enclosed	No	Enclosed	No
	GR	99/02166 A	01/1999	WIPO	Dougherty				
	HR	96/33980 A	031/1996	WIPO	Gibson				
	IR								
	JR								
	KR								
	LR								
	MR								
	NR								
	OR								
	PR								

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

QR	Ciardiello et al., "A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor", Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, vol. 7, no. 10, October 2001, pp. 2958-2970, XP002248479, ISSN: 1078-0432				
RR					
SR					
TR					
UR					
VR					
WR					
XR					

Examiner	Date Considered:
----------	------------------

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.